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Abstract  
 
DARC (Duffy Antigen Receptor for Chemokines) is unusual transmembrane 
chemokine receptor which (i) binds the two main chemokine families and (ii) does not 
transduct any signal as it lacks the DRY consensus sequence. It is considered as silent 
chemokine receptor, a tank useful for chemiotactism. DARC had been particularly 
studied as a major actor of malaria infection by Plasmodium vivax. It is also 
implicated in multiple chemokine inflammation, inflammatory diseases, in cancer and 
might play a role in HIV infection and AIDS. In this review, we focus on the interest 
to build structural model of DARC to understand more precisely its abilities to bind 
its physiological ligand CXCL8 and its malaria ligand. We also present innovative 
development on VHHs able to bind DARC protein. We underline difficulties and 
limitations of such bioinformatics approaches and highlight the crucial importance of 
biological data to conduct these kinds of researches.  
 
 
 
 
 
 
 
 
 
Keywords: transmembrane protein, comparative modelling, bioinformatics, protein 
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Résumé  
 
Le DARC (Duffy Antigen Receptor for Chemokines) est un récepteur aux 
chimiokines inhabituel qui (i) lie les deux grandes familles de chimiokines et (ii) du 
fait de l’absence du motif DRY ne transduit pas de signal. Récepteur silencieux, il est 
un réservoir utile pour le chimiotactisme. DARC a été particulièrement étudié comme 
un acteur majeur de l'infection par Plasmodium vivax. Il est également impliqué dans 
des maladies inflammatoires, cancers et pourrait jouer un rôle dans l'infection par le 
HIV. Nous présentons l'intérêt de construire un modèle structural de DARC, pour 
comprendre plus précisément sa capacité à lier son ligand physiologique CXCL8 et 
son ligand paludique. Nous présentons des développements innovants portant sur des 
VHHs capables de lier le DARC. Nous soulignons aussi les difficultés et les limites 
des approches bioinformatiques et mettons en évidence l'importance cruciale de 
données biologiques pour mener à bien ce type de recherches. 
 
 
 
 
 
 
 
 
 
Mots-clés: protéine transmembranaire, modélisation comparative, bioinformatique, 
assemblage protéique, assemblage flexible, VHHs de camélidés, paludisme, cancer. 
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DARC 
The history of human knowledge on DARC (Duffy Antigen Receptor for 
Chemokines) begins in 1950 with the discovery of a new blood groups system (the 
Duffy blood group system) named from the person who developed the first antibody 
against the so called Fya antigen [1]. A second antithetic antigen Fyb [2] was shortly 
after discovered. In 1955, it was shown that antigens of Duffy blood group system 
were missing in red blood cells (named Fy(a-b-)) from a large proportion of West 
African ascent population (RBC-WAAP) [3]. It was observed thereafter that these 
cells were resistant to invasion by Plasmodium vivax (see below). Other important 
steps were cloning of cDNA coding for the protein carrying the Fy antigens, the 
Duffy glycoprotein, the recognition that Duffy glycoprotein was a transmembrane 
receptor for chemokines leading to changing its name to DARC. 
In this short review, we will briefly overview knowledge on the immunogenic 
properties of DARC, relations of DARC with malaria, of DARC with chemokines 
inflammation and inflammatory diseases. We will quote present research which deals 
with the multiple roles of this somewhat enigmatic protein that, besides malaria and 
inflammation, is implicated in cancer and might play a role in HIV infection and 
AIDS. Then, we show the interests in the design of structural models for DARC 
analysis. We will present (i) how to build proper structural models of DARC [4], (ii) 
how to elucidate pertinent interactions with its ligands [5] and (iii) what might be the 
role of structural modelling in elaboration of new tools for DARC studies [6]. 
 
Duffy antigens.  
They have been defined by studying reactivity of patients immunized through 
transfusion or pregnancy. Fya/Fyb allotypic variants exist and correspond to a SNP in 
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exon 2 encoding a Gly42Asp substitution in the extracellular N-terminal domain of 
the Duffy glycoprotein [7, 8]). Two other antigens have been identified: (i) Fy3, 
which involves residues from the 3rd extracellular loop [9], is probably a 
conformational reader and (ii) Fy6, which was discovered after immunisation of mice 
with human red cells or engineered eukaryotic cells expressing DARC, is a linear 
epitope contained in the first extracellular domain. Fy6 is present both in Fya or Fyb 
allotype, and, only Fy(a-b-) cells do not react with anti Fy6. 
The mechanism of selective extinction of expression of Duffy related antigens 
on WAAP red cells have been elucidated. The Duffy negative phenotype of WAAP 
red cells (noted Fy(a-b-)) is due to homozygosity for a promoter polymorphism (-
46C) in which the binding site for the  transcription factor (GATA-1), required for 
DARC to be expressed on the cell surface of erythrocytes [10], is disrupted. This 
mutation is present in a Fyb genetic background. Importantly in Fy(a-b-) WAAP, 
DARC is normally expressed on cells in which DARC expression was already 
demonstrated for example, endothelial cells of post capillary veinules, epithelial cells 
of collecting ducts of the kidney, cerebellar Purkinje cells [11, 12]. Another promoter 
is likely operative in these tissues. 
 
DARC and Plasmodium vivax. DARC was characterized as an erythrocyte 
receptor for malaria parasite through in vitro studies and also in vivo experiments 
performed on American volunteering detainees [13, 14]. The hypothesis that DARC 
might be a receptor for P. vivax raised after it was noted that WAAP might be 
resistant to infection by P. vivax purportedly performed to treat neuro syphilis. All 
this does support the widely accepted hypothesis that P. vivax was the driving force 
for fixing the mutation silencing red cell expression of DARC. In this regards, it is 
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interesting to note that in Papua New Guinea, where P. vivax malaria is also endemic, 
heterozygous individuals for the same GATA-1 site mutation have been found [15] 
but on a Fya background. It is tempting to speculate that the same FY GATA-1 
mutation in Africans and Melanesians occurred independently in these two 
populations as a result of the same selection pressure.  
Plasmodium vivax Duffy binding protein (PvDBP) is a merozoite microneme 
ligand vital for blood-stage infection, which makes it an important candidate vaccine 
for antibody-mediated immunity against vivax malaria [16, 17]. Naturally acquired 
antibodies to DBP seem to confer protection from blood-stage P. vivax infection, 
supporting the development of a vaccine against P. vivax malaria [18]. However other 
studies also pinpointed that produced human antibodies might have low efficiencies 
underlining the difficulty of vaccine design [19]. Hence, alternative approaches to 
interfere with P. vivax merozoite with DARC on red cells are demanded. 
Consequently, analysis of interaction mechanisms between DARC and DBP is 
important; analysis of DBP variants and DARC genotypes gives also insights to the 
sequence – function relationship [20]. 
Very recently, studies have shown that in Madagascar, P. vivax can invade Fy(a-
b-) erythrocytes leading to disease [21]. Further studies are necessary to identify the 
genetic peculiarities of the parasite strain the receptors that enable this DARC-
independent P. vivax invasion of human erythrocytes. 
Beyond DARC and PvDBP it is worth to notice the existence of Duffy-Binding 
like (DBL) domains implicated in other types of malaria. Domains related to PvDBP 
are found in Plasmodium falciparum. DBL domains are conserved regions of 
erythrocyte membrane protein 1 (PfEMP1) family. VAR2CSA Duffy binding-like 
(DBL) domains, which bind chondroitin sulphate A in placenta, are interesting 
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candidates for the development of a vaccine against pregnancy-associated malaria 
[22]. Indeed, in spite of the extreme polymorphism of PfEMP1 DBL  domains, 
specific antibodies reducing risk of malaria in areas with high transmission rates were 
acquired [23]. DBLs family fold is supposed to be conserved. Consequently, the 
family is intensively studied to elucidate binding mechanisms [24-27].  
 
DARC and chemokines. DARC is a transmembrane receptor for a variety of 
chemokines of both CXC and CC classes, including angiogenic (ELR
+
) CXC 
chemokines, but not angiostatic (ELR
-
) CXC chemokines [28, 29]. DARC sequence is 
quite different from other chemokines receptors [30, 31]. It is a silent chemokine 
receptors (or interceptors) [29]. Besides, a clear distinction should be made between 
DARC expressed on red cells and DARC expressed in other tissues. Importantly, 
DARC is lacking the DRY consensus sequence that is necessary to activate a protein 
G dependant activation cascade after activation by ligand binding [8, 32-34]. DARC 
on red cells does not internalize. DARC might play the role of a buffer or a scavenger 
for chemokines and could reduce their concentration in blood stream [35]. By contrast 
DARC on endothelial cells behaves differently. It supports transcytosis of chemokines 
from luminal to extravascular space and favours leucocyte migration and development 
of inflammatory reactions [36]. A similar mechanism might operate in in vitro model 
of rheumatoid arthritis in which overexpression of DARC does favour inflammatory 
reaction [37]. DARC could play a role in inflammatory diseases of the kidney [38]. 
Heterodimerization of DARC with CCR5 might impair activation of 
intracellular signalling dependant on chemokine binding to CCR5 [39]. This 
observation definitely adds a level of complexity and makes the role of DARC 
difficult to understand. 
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Evidence strongly supports that DARC might play role(s) in the delicate 
interplay of chemokines and chemokines receptors (chemokines network). DARC is 
definitely considered to be important in a range of physiological and pathological 
conditions. 
 
DARC and HIV. HIV binding was early reported [40, 41]This binding, which is 
inhibitable by CXCL8 8 and anti FY6 antibody [41], might help the viral infection of 
CD4+ sensitive cells. Later results confirmed that red cell binding to HIV might 
favour HIV trans-infection of susceptible cells. However no difference was observed 
when comparing Fy(a+b+) and Fy(a-b-) cells [42]. Epidemiological studies did 
suggest that the Duffy-null state is associated with a survival advantage in HIV-
infected persons of African ancestry [41, 43], but this proposition is also still highly 
debated [44-46].  
 
DARC and cancer. Recently, a relation between DARC and various cancers 
was established, making DARC a hot topic. Hence, it seems that DARC and murine 
CXC Chemokine Receptor-2 Receptors have opposite role in murine melanoma tumor 
growth [47, 48]. Epidemiological studies showed that African Americans are 
suffering from prostate cancer earlier than Caucasians. Moreover, the course of the 
disease appears more aggressive for African American population. These observations 
suggested that DARC might play a role in cancer. These observations were backed up 
by crossing DARC null engineered mice with TRAMP mice which developed 
spontaneous prostate cancer [28]. The scavenger role of DARC for chemokines to 
excess in red cells could participate in reducing angiogenesis, and consequently the 
progression of prostate cancer, by clearing angiogenic chemokines from the tumour 
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microenvironment [28, 49]. Hypothesis has been discussed on the substantially higher 
levels of prostate cancer and associated mortality rates in men of African origin 
compared with Caucasian men. On the other hand, expression of DARC in breast 
cancer tumour cells does lower metastasis and aggressiveness of the tumour [50]. 
Again, interaction of DARC with chemokines is hypothesized to explain a putative 
role of DARC in cancer progression noticeably angiogenic chemokines that are 
obviously implicated in tumour neovascularisation. 
 
The different aspects of the research 
All these data clearly suggests that DARC is a particularly interesting and 
important protein. Various DARC mutants have been designed and expressed. 
Affinities with DARC natural ligand, CXCL8, and different antibodies [33, 51-58] 
confirmed predictions made about DARC topology [59]. This transmembrane protein 
as bona fide GPCR has 7 transmembrane segments with four extracellular loops 
(named Extra Cellular Domains or ECDs) and four intracellular loops (named Intra 
Cellular Domains or ICDs). The first ECD (ECD1) is a long Nterminal segment, 
while last ICD (ICD4) is a short cytosolic Cterminal.  
Structural information can help a lot to understand its function and implications 
in diseases [60]. However, few transmembrane protein structures (~ 650 structures, 
1% of the Protein Databank [61-63]) are nowadays available [64, 65]. Due to the 
membrane environment [66-69] that stabilises the 3D fold, it is particularly difficult to 
extract, to purify to crystallise and finally to solve transmembrane proteins structures 
by X-ray crystallography. Hence, structural modeling is an obligatory but difficult 
step. With a low number of available 3D structures, automatic homology modeling 
cannot be applied to GPCR or GPCR-like molecules even though it was attempted: at 
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best position of transmembrane membrane domains may be predicted but no solid 
information on structure of loops may be gained. Thus, pertinent structural models of 
transmembrane proteins must be a human supervised process using classical 
approaches coupled with various secondary structure predictions, refinement of 
sequence alignment, and if possible considering helix – helix and helix – lipid 
interactions. Importantly, experimental data are necessary for building relevant 
models [70]. 
In the next section, we will detail a concrete application and explain how 
experimental data were crucial for building pertinent structural models [4]. These 
models were particularly helpful to explain DARC interaction with its ligands. We 
will present the principle of docking methods applied to this kind of protein and the 
specific difficulties met when dealing with DARC [5]. Finally, we will discuss the 
interest of proposing structural models of camelids VHHs shown to bind a specific 
DARC epitope [6]. 
 
Building structural models 
Classically, a structural model can be elaborated through different strategies 
from homology/comparative modelling, threading ab initio or de novo approaches, 
depending on the sequence identity and the availability of structural homologous. 
Figure I shows a rough description of the sequence identity needed for each of these 
approaches. If the sequence identity is high, homology modelling could be used. In 
the twilight zone, when PSIBLAST is unable to detect any interesting sequences, 
threading approach could help to find distant homology by evaluating sequence-
template structure fold compatibility. In case of failure, ab initio modelling becomes 
the only possibility. Ab initio methods do not require any 3D template, but physico-
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chemical and/or statistical potentials. The main problem consists in finding the native 
protein structure, i.e. the 3D structure with a minimum free energy. Some ab initio 
approaches try to mimic protein folding to find this minimum. These approaches are 
essentially successful for peptides and very small proteins. Otherwise, they are not 
performed due to search complexity. De novo approaches combined these different 
methods starting from domain detection, looking for fragments with similar sequences 
in PDB. A large set of fragments is generally considered. The next problem consists 
in appropriately combining these fragments. The combinatory becomes rapidly 
prohibitive as the size of the protein increases. Consequently, sophisticated algorithms 
aiming at solving this combinatorial problem are required. These methods give good 
results but need an important computer power. These different approaches are 
available on meta-servers that mainly combine multiple results from different 
softwares and/or servers [71, 72]. It has to be noticed that all these approaches were 
developed for globular proteins.  
For the building of DARC of structural models, we started with comparative 
modelling. The procedure first consists in searching for homologous sequences in 
PDB. However, classical tools did not provide any convincing answer. The sequence 
identity between DARC and rhodopsin (PDB code: 1F88 [73]), the paradigm for 7-
TM fold, was very low, i.e., only 12% in the range of random alignment). 
Consequently, sequence alignment was not meaningful and no clear homology could 
be inferred. Moreover, DARC family members were too few to detect important 
conserved residues from divergent ones with the sole alignment. Consequently, the 
absence of real sequence divergence makes the alignment not truly informative. 
Actually, pertinent structural models could not be properly built with the sole 
sequence information of DARC. However, for DARC, important biological data were 
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available. Indeed, more than 40 different punctual DARC mutants were 
experimentally tested for affinity with natural ligands or some antibodies [9, 53, 74], 
they underline the potential accessibility of some residues. With this information, it 
was possible to guide the building of structural models. Figure II presents the main 
principle of the structural model building. 
DARC was divided into three main domains: (i) ECD1, (ii) one central domain 
encompassing the transmembrane helices and connection loops, and (iii) ICD4. 
Putative helical transmembrane regions were located with dedicated prediction 
softwares (DAS [75], TopPred 2 [76, 77], HMMTOP [78, 79], TMHMM 1.0 and 2.0 
[80], PHDtm [81, 82], TMpred [83], SOSUI [84-86], SPLIT [87, 88], Pred-TMR 1.0 
and 2.0 [89, 90], TMAP [91, 92], TSEG [93], TM-FINDER [94], UMDHMM
TMHP
 
[95], MEMSAT [96, 97], PRODIV-TMHMM [98] and MemBrain [99]). All these 
methods claim to be efficient with significant prediction rates when tested on 
benchmark datasets. Only the first helix is predicted with a large consensus. The 
fourth helix was particularly difficult to delimit. Other helices could also diverge by 
an impressive number of residues, i.e., 15 residues. The most recent prediction tools, 
e.g., MINNOU [100] were not necessarily the most efficient ones. Indeed, in some 
cases, PSI-PRED [101] mainly trained on globular protein, could give better results 
than dedicated approach, as seen in [102].  
In a second step, using a rough consensus definition of transmembrane regions, 
predicted helices were aligned with assigned transmembrane helical (DSSP software 
[103])segments of rhodopsin (PDB code 1F88 [73]). Strong efforts were dedicated to 
the prediction of ECD1 and ICD4 [104, 105]. Hundred models were generated using 
Modeller software [106-108]. Each model was then refined: (i) the side chains were 
repositioned using one of the most efficient approach, i.e., SCWRL [109]. We 
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performed simulated annealing for exploring connection loops conformations using 
GROMACS software [110, 111]. The residue accessibility was computed with 
Naccess software [112] and the results were compared to experimental data available. 
We focused on residues involved in antibody binding that are supposed to be 
accessible. The alignment was then modified accordingly. Twelve generations of 
alternative alignments were tested for finally obtaining two structural models that 
diverge by the topology of ECD1. (see Figure III [113]). In these two models, the 
accessibility values of important residues were large enough to allow binding. 
Since, novel approaches have been developed and adapted to transmembrane 
proteins. We revisited our models at the light of the most efficient new tools and 
compared with our results. For this purpose, we tested LOMETS (LOcal MEta-
Threading-Server [114]), a webserver that uses 8 different methods and ranks the 
results. Table I summarizes the different results obtained for MUSTER [115], SAM 
[116], PROSPECT2 [117], SP3 [118], PPA-I, HHsearch [119], SPARKS2 [120], and 
FUGUE [121]. The three first methods provide structural models with a medium 
confidence rate while the models constructed with the last methods are associated 
with a low confidence index. Only half of the proteins used as template are 
transmembrane proteins, half are globular proteins with often beta-sheets. Figure IV 
describes the main results obtained from LOMETS [114] and from PHYRE [122]. 
Figures IVa, IVd and IVg show the three templates found by LOMETS for the 
medium scored structural models. The first one is based on the famous human A2A 
adenosine receptor (PDB code 3EML [123]), while the two others are globular 
proteins, namely the COPI gamma-subunit (PDB code 1PDZ [124]) and cell vibrio 
mixtus mannosidase 5A (PDB code 1UUQ [125]). Figures IVb and IVc show the 
final structural model obtained from A2A adenosine receptor template. The fold 
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corresponds to a seven-segment transmembrane protein with ECD1 in an extended 
conformation. In both models, the first helix is well predicted, but many differences 
are observed in the positions of the following helices.  Nevertheless, these models are 
good starting points to build pertinent structural models. For the structural model 
based on COPI gamma-subunit (see Figures IVe and IVf), the difficulty to obtain 
transmembrane protein model is clearly illustrated. Finally, no structural model based 
on cell vibrio mixtus mannosidase 5A was obtained, i.e., the alignment being too 
poor. PHYRE, a powerful threading approach, proposed the well-known bovine 
rhodopsin structure as a template (PDB code 1U19 [126]) associated with 60 % 
confidence rate. However, in this structural model presented on Figure IVh, the TM 
helices were too long or too short helices, compared to what is classically expected 
for transmembrane protein. The 7-segment transmembrane topology was finally lost. 
These revisited models obtained with up-to-date methods show the importance 
of considering biological data to produce pertinent structural models. It also reinforces 
the validity of the structural models we constructed some years ago. 
 
Structural properties of DARC 
To explore the flexibility of the ECD loops, we performed simulated annealing 
simulations [127]. Interestingly, the procedure highlights the importance of residue 
D263 which was never really accessible in any structural models; this residue 
constrains the local fold by creating a bridge with ECD3. Analysis of simulations with 
Protein Blocks [104, 128] showed that that some regions in ECD1 tent to be more 
helical and other ones to be more extended. These results correlated well with the 
predictions done [105, 129, 130]. 
 - 15 - 
The two extreme positions of ECD1 (see Figure III) could also reflect also the 
domain motions [60]. We performed normal mode analysis (NMA) using different 
webservices. This methodology has been recently re-popularized and successfully 
applied for examining dynamics of large systems and also for transmembrane proteins 
[reference]. Among the different webservers, WEBnm@ server [131] provides 
additional analysis dedicated to transmembrane protein.  For this review, we also 
tested Nomad-Ref [132] and ElNemo [133, 134]. In NMA, the lowest frequencies 
modes are associated with the largest amplitude of motions. a large domain motion of 
ECD1 that gets closer to the other ECDs was observed with the different NMA tools. 
A similar motion was indeed observed with Nomad-Ref [132] or ElNemo [133, 
134].The main difference with Webnm@ lies in the ranking of the motions with 
respect to the frequency that were slightly different depending on the tool. The three 
regions detected with simulated annealing (a first structured zone, a transition region 
and a last structured zone) are clearly involved in the motion. The median region 
plays a role of hinge between the two extremities of ECD1. Figure V illustrates the 
motions associated with the two of the lowest modes given by ElNemo [133, 134]. On 
the left side is indicated the hinge region. The movements are schematized in the two 
following Figures. In both, the flexible hinge region moves with respect to the two 
structured regions. 
Electrostatic potentials of DARC model and its natural ligand CXCL8 were 
calculated using the finite-difference Poisson-Boltzmann (FDPB) method [135]. Two 
distinct zones can be observed in potential interaction zones with CXCL8. The first 
one is highly negative and encompass the residues implicated in epitope Fy6. The 
second one is highly positive. CXCL8 also shows two regions with opposite features 
(one positive and the remainder negative, encompassing the loop 40s known to 
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interact with chemokine receptor). Our results highlight regions with significant 
electrostatic properties in agreement with experimental studies that underline the 
importance of electrostatics in the binding of chemokines [136, 137]. 
A following question is the potential use of such structural models for 
understanding the binding of DARC and its ligands. Docking methods are particularly 
appropriate to locate binding sites on both partners and their relative orientation, even 
though the use of models increases the risk of obtaining irrelevant structures of 
complex. Docking procedure roughly consists in moving the smallest partner 
(designed as “the ligand”) on the surface of the largest molecule (“the receptor”). For 
each position, a score (or energy) is computed. The position with the optimal score is 
finally selected. A source of errors comes from the inadequacy of scoring to represent 
binding energies. In addition, most docking at least in the first steps, consider the 
partners as rigid. This limitation is only alleviated in a final refining step when a 
subset of solutions has been already established. In the case of DARC, we previously 
underlined that ECD1 is highly flexible. Clearly, this property must be accounted.  
Consequently, we performed the study in two steps and we designed a docking 
approach that combines rigid and flexible docking. In a first step, DARC structural 
model is cut into ECD1 and the rest of the protein (see Figure VIa) to find correct 
positioning of CXCL8 on DARC without ECD1, and a flexible docking only with 
ECD1 and CXCL8 (see Figure VI). On one side, a flexible docking of ECD1 is done 
with structure of CXCL8 (see Figure VIb) thanks to ICM [138, 139] software. It is 
very difficult and complex approach with a very high computing consuming time. On 
the other side, a rigid docking is done with the transmembrane domain of DARC (see 
Figure VIc) thanks to ClusPro [140, 141] webserver. Each experiment give numerous 
possibilities, the docking conserved where selected on energetic properties of the 
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complex and also using biological data. Figure VII shows examples of results of rigid 
docking (see Figure VIIa and VIIb) and of final combination of rigid and flexible 
docking (see Figure VIIc and VIId). These results were quite encouraging. Finally, 
both results will be combined to perform a deeper search [60]. Further optimization 
needs to be done, but conserved results are in accordance with expected residues in 
contacts. 
 
Modelling of camelid VHHs 
DARC is implicated in numerous human diseases. Dedicated tools are 
demanded for analyzing DARC role and guiding therapeutic strategies. In this field, 
antibodies and their recombinant derivatives are of great use. The heavy chain-only 
antibodies found in camelids are composed of heavy chains and lack all light chains 
[142]. VHHs (or nanobodies), which correspond to the domain in the heavy chain-
only antibody, can be derived. In this domain is located the antigen recognition 
region. VHHs are easily cloned from lymphocytes from naive or immunized 
camelids; they can be expressed in E. coli with a good yield and have an excellent 
solubility [143]. Moreover, they have proved to be efficient as therapeutic and 
diagnostic agents [144, 145]. 
A dromedary has been immunized with ECD1 of DARC expressed in E. coli. 
As presented earlier, ECD1 carries several sites important to DARC functions and 
properties (binding to chemokines and PvDBP, Fya/Fyb allotypes, the Fy6 epitope). 
A VHH library from dromedary's lymphocytes was built and screened using also E. 
coli expressed proteins for DARC specific VHHs. Several clones were obtained, 
especially one named CA52. CA52 is able to recognize the glycosylated protein 
present on human cells, even if the constructs used for immunization and screening 
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was non glycosylated proteins. The linear epitope recognized by CA52 was identified 
and overlaps the well known Fy6 antigen. CA52 interferes with the CXCL8 binding 
to DARC and P. vivax infection of red blood cells [6]. 
To more deeply analyze CA52 and to get a glimpse into its putative interactions 
with DARC, we constructed a structural model of CA52 VHH. A classical 
comparative modelling approach was carried out as available VHH structures sharing 
a good sequence identity with CA52 are available. From a structural point of view, 
VHHs adopt a well-characterized topology composed of four very constant regions 
and three hypervariable regions (CDR1 to CDR3). These last ones correspond to the 
binding part of VHHs that recognize the epitope (here ECD1). Constant region fold 
corresponds to a series of -sheets that is found in all VHHs and gives the topology of 
the protein. Figures VIIIa and VIIIb shows an example of a VHH [146], in green the 
constant regions, and in yellow, orange and red, CDR1 to CDR3. Figures VIIIc 
highlight the protein interface which binds the epitope.  
Sequences related to CA52 were searched with PSI-BLAST software [147] 
applied on Protein DataBank [61]. Using default parameters of PSI-BLAST, one 
VHH (PDB code 1XFP [148]) was selected with a very good sequence identity 
(75%). However, all the structural models obtained presented a topology inversion 
between two loops. A careful analysis of PSI-BLAST results showed that CDR3 
regions were considered as non-informative (i.e., coiled-coil as detected by SEG 
[149]) although this CDR is the most important one for the binding. When SEG was 
disabled, PSI-BLAST search gave VHHs structural templates better matching for 
CDR3 (both in length and sequence identity). A first structure (PDB code 1OP9 
[146]) was selected (a sequence identity of 75% and a good alignment with CDR3). 
Figure VIIId underlines the huge impact of the fine analysis of VHHs. CDR3 of VHH 
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1XFP is shown in yellow and exhibits a classical -sheet, while in 1OP9 template 
structure, CDR3 of VHH (shown in red) has helical tendencies (mainly a succession 
of -turns). Moreover, these regions are totally differently positioned. This example 
illustrates the importance of a precise analysis of templates and of a good knowledge 
of bioinformatic tools.  
A very important point for guiding the structural modelling was the 
experimental characterization of an extra-disulfide bridge between Cysteines 33 and 
107. This disulfide bond is of major biological importance. We considered a second 
template to 1OP9, namely 1JT0 [150] that possesses a similar extra-disulfide bridge. 
The protein sequences were aligned with Clustalw2 software [151] and some manual 
changes were done. The model construction was performed with the Modeller 
software [107]. Final structural models showed few differences as constant regions 
strongly constrained the topology and the extra-disulfide bridge constraints strongly 
CDRs. Topology was assessed using ProCheck software [152]. Figure VIIIe shows 
the final model. CDR3 is composed of series of -turns (the disulfide bridge is in blue 
colour). Figure VIIIf shows the distribution of charges at the surface. CDR2 and 
CDR3 present a strong positive surface (blue colour) as the central part of CDR1. 
Molecular modelling of another VHH sequence that binds the same epitope but with 
lower affinity gives some hints about important residues. The presence of a positive 
surface in this region and the presence of a negative surface in the linear target 
peptide (see Structural properties of DARC section) are suggestive for important 
electrostatic interactions. 
 
 
 
 - 20 - 
Conclusions and Perspectives 
Hence, in this short review, we have presented the biological importance of 
DARC protein and its multiple implications in human diseases. We have underlined 
the interest to use structural models to better understand this protein. The building of a 
structural model for a transmembrane protein is a very difficult task. Comparison with 
up-to-date methods highlights the crucial value of biological data to produce pertinent 
structural models, our approach remaining the most efficient one. Using these models, 
we have shown the capabilities of new and complex methodology combining classical 
rigid docking and novel flexible docking. Additional simulations must be done to 
confirm these preliminary results, but these last one are already quite encouraging, 
with a very good agreement with experimental data. Finally, we have opened new 
perspectives given by the use of structural models of camelid VHHs able to bind 
DARC. We plan to analyze each sequence of VHHs obtained in a similar way to 
understand more precisely the most important residues involved in the recognition of 
ECD1. 
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Figures 
 
Figure I. Structural modeling methodology in function of sequence identity. 
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Figure II. Principle of DARC structural model building. (a) Prediction of transmembrane segments, the DARC sequence is divided into 7 transmembrane segments and 8 
loops. (b) The rhodopsin structure is also cut into transmembrane segments and loops. (c) Each segment is aligned independently with its counterparts. ECD1 and ICD4 are 
treated separately with other approaches (see text). A global alignment is done and used to generate structural models. (d) Structural models are optimized and important 
residues are manually analyzed. The alignment is then manually modified and new structural models are generated. The process is done until most of the concerned residues 
are accessible. 
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Figure III. The two selected structural models. They are shown thanks [113] to PyMol software . (a) open form, (b) closed form. 
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Figure IV. Results of LOMETS and FUGUE webservers. (a), (d) and (g): 
structural templates used by LOMETS [114] for its medium quality structural models. 
(a): human A2A adenosine receptor (PDB code 3EML [123]), (d) COPI gamma-
subunit (PDB code 1PDZ [124]), (g) cell vibrio mixtus mannosidase 5A (PDB code 
1UUQ [125]). (b) and (c) two views of the structural model based on human A2A 
adenosine receptor (PDB code 3EML [123]), (e) and (f) two views of  the structural 
model based on COPI gamma-subunit (PDB code 1PDZ [124]). (h) the structural 
model based on bovine rhodopsin structure (PDB code 1U19 [126]) obtained by 
PHYRE [122]. 
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Figure V. Two low modes computed with ElNemo. (a) and (c) initial structure, 
the hinge is pointed by the arrows, (b-c) and (e-f) motions observed with these modes, 
the arrows indicated the nature of the observed movements. 
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Figure VI. Principle of our docking approach. (a) the structural model of DARC is split into two parts (ECD1 and transmembrane region). 
(b) flexible docking is performed between ECD1 and CXCL8. (c) rigid docking of CXCL8 is done with transmembrane domain of DARC. (d) 
best results of each approaches are combined and then optimized. 
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Figure VII. Two examples of docking results. (a) and (b) two views of an 
example of a rigid docking of monomeric CXCL8 (green color) with transmembrane 
domain of DARC (helices in red, loops in blue and beta-strand in yellow). (c) and (d) 
two views of an example of a combination of rigid and flexible docking of dimeric 
CXCL8 (green and orange color) with transmembrane domain of DARC. 
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Figure VIII. Camelid VHHs and structural model. (a) and (b) two views of an VHH, CDR1 is in yellow, CDR2 in orange and CDR3 is 
red, the rest is in green. (c) surface representation of the same protein. (d) Comparison between the two potential templates, noted (1) is the 
original one which corresponds to -sheet conformation (in yellow), while (2) is the correct one (in red). (e) Selected structural model, the extra-
disulfide bridge is in blue. (f) Electrostatics surface. 
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Table I. Results of LOMETS webserver. 
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